The significance of prestroke aspirin dosage in fatal outcome of acute stroke

Clinical Neuropharmacology

Volumn 28, Issue 2, 2005, Pages 55-59

  Lampl, Yair ^a,b   Boaz, Mona ^a   Sadeh, Menachem ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Aspirin; Mortality; Outcome; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ASCRIPTIN; CLOPIDOGREL; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; MICROPIRIN; TEVAPIRIN; TICLOPIDINE;

ADULT; AGED; ANTICOAGULANT THERAPY; BLEEDING; BLOOD VESSEL OCCLUSION; BRAIN INFARCTION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GENDER; HEALTH CARE FACILITY; HEART ARRHYTHMIA; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PARAMETER; PRIORITY JOURNAL; PUBLIC HOSPITAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ASPIRIN; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 16344380742     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000157068.89066.a3     Document Type: Review

References (27)

1. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
2. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ. 2002;324:71-86.
4. Multicentre Acute Trial (MAST-1) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
5. Rosenblum WI, El-Sabban F. Platelet aggregation in the cerebral microcirculation: effect of aspirin and other agents. Circ Res. 1977;40: 320-328.
6. Joseph R, D'Andrea G, Oster SB, et al. Whole blood platelet function in acute ischemic stroke: importance of dense body secretion and effects of antithrombotic agents. Stroke. 1989;20:38-44.
7. Regional WHO office for Europe and the European Stroke Council. Report on Pan European Consensus Meeting on Stroke Management, Helsingborg, Sweden, November 1995. Copenhagen, Denmark: World Health Organization; 1996.
8. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definition for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
9. Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in the adult (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
10. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32:803-808.
11. Karepov V, Bornstein NM, Hass Y, et al. Does daily aspirin diminish severity of first-ever stroke? Arch Neurol. 1997;54:1369-1371.
12. Wilterdink JL, Bendixen B, Adams HP, et al. Effect of prior aspirin use on stroke severity in the trial of org 10172 in acute stroke treatment (TOAST). Stroke. 2001;32:2836-2840.
13. Dougherty JH, Levy DE, Weksler BB. Platelet activation in acute cerebral ischemia: serial measurements of platelet function in cerebrovascular disease. Lancet. 1977;1:821-824.
14. Joseph R, Han E, Tsering C, et al. Platelet activity and stroke severity. J Neurol Sci. 1992;108:1-6.
15. Riepe M, Phys D, Kasischke K, et al. Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke. 1997;28:2006-2011.
16. De Cristobal J, Cardenas A, Lizasoain I, et al. Inhibition of glutamate release via recovery of ATP levels accounts for a neuroprotective effect of aspirin in rat cortical neurons exposed to oxygen-glucose deprivation. Stroke. 2002;33:261-267.
17. Grilli M, Pizzi M, Memo M, et al. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science. 1996;274:1383-1385.
18. Gomes I. Aspirin: a neuroprotective agent at high doses? Natl Med J India. 1998;11:14-17.
19. Futterman LG, Lemberg L. Inflammation in plaque rupture: an active participant or an invited guest? Am J Crit Care. 1998;7:153-161.
20. Cha JK, Jeong MH, Lee KM, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis. 2002;14:145-150.
21. Jialal I, Devaraj S. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol. 2001;116(suppl):S108-S115.
22. Bamford J, Dennis M, Sandercock P, et al. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry. 1990;53:824-829.
23. Bronnum-Hansen H, Davidsen M, Thorvaldsen P for the Danish Monica Study Group. Long-term survival and causes of death after stroke. Stroke. 2001;32:2131-2136.
24. Longstreth WT Jr, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5888 participants in the Cardiovascular Health Study. Neurology. 2001;56:368-375.
25. Sacco RL, Sli T, Zamanillo MC, et al. Predictors of mortality and recurrences after hospitalized cerebral infarction in an urban community: the Northern Stroke Study. Neurology. 1994;44:626-634.
26. Petty GW, Brown RD Jr, Whisuaht JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival and recurrence. Stroke. 2000;31:1062-1068.
27. Kolomisky-Rabas PI, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32:2735-2740.